Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient demographics and disease

From: Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer

Patient Primary tumor Resected metastatic site for generation of vaccine Time from initial diagnosis of disease to vaccine treatment (wks) Time from diagnosis of stage IV disease to vaccine treatment (wks) Number of previous surgical treatments for disease Previous chemotherapy regimens
1 Colon Liver 30 21 2 FOLFOX
FOLFIRI
Bevacizumab
Capecitabine
2 Colon Peritoneum, Liver 161 161 4 XELOX
XELIRI
Bevacizumab
3 Colon Peritoneum 119 119 2 FOLFOX
FOLFIRI
Bevacizumab
4 Rectal Peritoneum, Liver, Lymph Nodes 374 282 6 FOLFOX
FOLFIRI
Cetuximab
Capecitabine
5 Colon Peritoneum, Colon 161 161 3 FOLFOX
FOLFIRI
Bevacizumab
6 Colon Peritoneum 152 152 3 FOLFOX
FOLFIRI
Bevacizumab
Capecitabine
7 Colon Pancreas, Peritoneum 208 208 5 FOLFOX
FOLFIRI
Cetuximab
Bevacizumab
Capecitabine
8 Rectal Peritoneum, Small Bowel, Lymph Nodes 344 150 4 FOLFOX
FOLFIRI
Capecitabine
9 Rectal Peritoneum, Liver 163 141 3 FOLFOX
FOLFIRI
Bevacizumab